FR2651435A1 - Nouvelle utilisation de composes anti-progestomimetiques. - Google Patents
Nouvelle utilisation de composes anti-progestomimetiques. Download PDFInfo
- Publication number
- FR2651435A1 FR2651435A1 FR8911699A FR8911699A FR2651435A1 FR 2651435 A1 FR2651435 A1 FR 2651435A1 FR 8911699 A FR8911699 A FR 8911699A FR 8911699 A FR8911699 A FR 8911699A FR 2651435 A1 FR2651435 A1 FR 2651435A1
- Authority
- FR
- France
- Prior art keywords
- radical
- use according
- carbon atoms
- progestomimetic
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims description 15
- 230000016087 ovulation Effects 0.000 claims abstract description 4
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 33
- -1 hydrocarbon radical Chemical group 0.000 claims description 32
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 28
- 150000003254 radicals Chemical group 0.000 claims description 23
- 239000000186 progesterone Substances 0.000 claims description 16
- 229960003387 progesterone Drugs 0.000 claims description 16
- 229910052799 carbon Inorganic materials 0.000 claims description 13
- 241001465754 Metazoa Species 0.000 claims description 10
- 239000004215 Carbon black (E152) Substances 0.000 claims description 6
- 244000309465 heifer Species 0.000 claims description 6
- 229930195733 hydrocarbon Natural products 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 5
- 230000000962 progestomimetic effect Effects 0.000 claims description 5
- DBLOJPKZEOYNBN-SQNIBIBYSA-N (8s,13s,14s)-13-methyl-2,6,7,8,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 DBLOJPKZEOYNBN-SQNIBIBYSA-N 0.000 claims description 4
- 241000283690 Bos taurus Species 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 101100490437 Mus musculus Acvrl1 gene Proteins 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 230000012173 estrus Effects 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 claims description 4
- 150000003431 steroids Chemical class 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 3
- 231100000535 infertility Toxicity 0.000 claims description 3
- 208000000509 infertility Diseases 0.000 claims description 3
- 230000036512 infertility Effects 0.000 claims description 3
- 125000006017 1-propenyl group Chemical group 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical group [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000004043 oxo group Chemical group O=* 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 229910052710 silicon Inorganic materials 0.000 claims description 2
- 239000010703 silicon Substances 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 238000009395 breeding Methods 0.000 claims 1
- 230000001488 breeding effect Effects 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 11
- 229960002897 heparin Drugs 0.000 description 11
- 229920000669 heparin Polymers 0.000 description 11
- 229960005309 estradiol Drugs 0.000 description 6
- 229930182833 estradiol Natural products 0.000 description 6
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000003556 assay Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000017448 oviposition Effects 0.000 description 2
- WPWHSFAFEBZWBB-UHFFFAOYSA-N 1-butyl radical Chemical compound [CH2]CCC WPWHSFAFEBZWBB-UHFFFAOYSA-N 0.000 description 1
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 201000005670 Anovulation Diseases 0.000 description 1
- 206010002659 Anovulatory cycle Diseases 0.000 description 1
- HNUALPPJLMYHDK-UHFFFAOYSA-N C[CH]C Chemical compound C[CH]C HNUALPPJLMYHDK-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 208000011707 Ovulation disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 231100000552 anovulation Toxicity 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8911699A FR2651435A1 (fr) | 1989-09-07 | 1989-09-07 | Nouvelle utilisation de composes anti-progestomimetiques. |
| US07/578,894 US5173483A (en) | 1989-09-07 | 1990-09-05 | Ovulation stimulating method |
| EP90402449A EP0417003B1 (fr) | 1989-09-07 | 1990-09-06 | Utilisation de composés antiprogestomimétiques pour favoriser l'ovulation |
| DE69010294T DE69010294T2 (de) | 1989-09-07 | 1990-09-06 | Verwendung von Antiprogestomimetika zur Stimulierung des Eisprungs. |
| AT90402449T ATE107859T1 (de) | 1989-09-07 | 1990-09-06 | Verwendung von antiprogestomimetika zur stimulierung des eisprungs. |
| DK90402449.4T DK0417003T3 (da) | 1989-09-07 | 1990-09-06 | Anvendelse af antiprogestomimetiske forbindelser til fremme af ovulation |
| CA002024728A CA2024728A1 (fr) | 1989-09-07 | 1990-09-06 | Utilisation de composes anti-progestomimetiques |
| KR1019900014224A KR0180225B1 (ko) | 1989-09-07 | 1990-09-06 | 항프로게스테론양 화합물로 이루어지는 배란 자극용 제약조성물 |
| JP2236004A JP3032258B2 (ja) | 1989-09-07 | 1990-09-07 | 抗黄体ホルモン様活性を持つ化合物の新しい用途 |
| AU62259/90A AU623805B2 (en) | 1989-09-07 | 1990-09-07 | New use of anti-progestomimetic compounds |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8911699A FR2651435A1 (fr) | 1989-09-07 | 1989-09-07 | Nouvelle utilisation de composes anti-progestomimetiques. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2651435A1 true FR2651435A1 (fr) | 1991-03-08 |
| FR2651435B1 FR2651435B1 (enExample) | 1994-04-22 |
Family
ID=9385212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8911699A Granted FR2651435A1 (fr) | 1989-09-07 | 1989-09-07 | Nouvelle utilisation de composes anti-progestomimetiques. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5173483A (enExample) |
| EP (1) | EP0417003B1 (enExample) |
| JP (1) | JP3032258B2 (enExample) |
| KR (1) | KR0180225B1 (enExample) |
| AT (1) | ATE107859T1 (enExample) |
| AU (1) | AU623805B2 (enExample) |
| CA (1) | CA2024728A1 (enExample) |
| DE (1) | DE69010294T2 (enExample) |
| DK (1) | DK0417003T3 (enExample) |
| FR (1) | FR2651435A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2718138B1 (fr) * | 1994-04-01 | 1996-04-26 | Roussel Uclaf | Nouveaux stéroïdes comportant en position 20 une chaîne aminosubstituée, procédé et intermédiaires de préparation, application comme médicaments et compositions pharmaceutiques les renfermant. |
| ZA953976B (en) * | 1994-05-19 | 1996-01-19 | Akzo Nobel Nv | 11,21-bisphenyl-19-norpregnane derivatives |
| DE4434488A1 (de) * | 1994-09-14 | 1996-03-21 | Schering Ag | Steroidester und -amide, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
| US6900193B1 (en) * | 1996-05-01 | 2005-05-31 | The United States Of America As Represented By The Department Of Health And Human Services | Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents |
| WO1997041145A1 (en) * | 1996-05-01 | 1997-11-06 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | 21-substituted progesterone derivatives as new antiprogestational agents |
| WO2003055524A1 (en) * | 2001-12-21 | 2003-07-10 | Pantarhei Bioscience B.V. | Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method |
| EP1613640A4 (en) * | 2003-02-28 | 2010-05-19 | Us Gov Health & Human Serv | PROCESS FOR PREPARING 17 ALPHA-ACETOXY-11 BETA- (4-N, N-DIMETHYLAMINOPHENYL) -19-NORPREGNA-4,9-DIENE-3,20-DION, INTERMEDIATE PRODUCTS AND METHOD OF MANUFACTURING THESE INTERMEDIATE PRODUCTS |
| US20130029953A1 (en) * | 2011-07-28 | 2013-01-31 | Klaus Nickisch | Progesterone antagonists |
| US9096641B2 (en) | 2013-06-05 | 2015-08-04 | Evestra, Inc. | Imidazolyl progesterone antagonists |
| CN108699102A (zh) | 2015-12-23 | 2018-10-23 | 欧瑞克制药公司 | 糖皮质激素受体抑制剂 |
| WO2017112904A1 (en) | 2015-12-23 | 2017-06-29 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
| JP6995757B2 (ja) | 2015-12-23 | 2022-01-17 | オリック ファーマシューティカルズ，インク． | グルココルチコイド受容体の阻害剤 |
| DK3523315T3 (da) | 2016-10-07 | 2021-05-03 | Oric Pharmaceuticals Inc | Inhibitor af glucocorticoidreceptor |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0057115A2 (fr) * | 1981-01-09 | 1982-08-04 | Roussel-Uclaf | Nouveaux dérivés stéroides substitués en 11beta, procédé de préparation, leur application comme médicament et les compositions les renfermant |
| FR2566779A2 (fr) * | 1984-06-29 | 1986-01-03 | Roussel Uclaf | Nouveaux derives steroides substitues en 11b, leur procede de preparation et leur application comme medicaments |
| FR2625505A2 (fr) * | 1981-01-09 | 1989-07-07 | Roussel Uclaf | Nouveaux derives steroides substitues en 11beta leur procede de preparation et leur application comme medicaments et les compositions pharmaceutiques les renfermant |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2528434B1 (fr) * | 1982-06-11 | 1985-07-19 | Roussel Uclaf | Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament |
| DE3200459A1 (de) * | 1982-01-09 | 1983-07-21 | Hoechst Ag, 6230 Frankfurt | Verfahren zur behandlung der azyklie bei schafen oder rindern |
| FR2522328B1 (fr) * | 1982-03-01 | 1986-02-14 | Roussel Uclaf | Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments |
| US4833133A (en) * | 1986-05-22 | 1989-05-23 | Sterling Drug Inc. | Method of regulating fertility in cattle using epostane |
| DE3633244A1 (de) * | 1986-09-26 | 1988-03-31 | Schering Ag | Antigestagene zur hemmung der uterinen prostaglandinsynthese |
-
1989
- 1989-09-07 FR FR8911699A patent/FR2651435A1/fr active Granted
-
1990
- 1990-09-05 US US07/578,894 patent/US5173483A/en not_active Expired - Fee Related
- 1990-09-06 AT AT90402449T patent/ATE107859T1/de not_active IP Right Cessation
- 1990-09-06 CA CA002024728A patent/CA2024728A1/fr not_active Abandoned
- 1990-09-06 EP EP90402449A patent/EP0417003B1/fr not_active Expired - Lifetime
- 1990-09-06 DE DE69010294T patent/DE69010294T2/de not_active Expired - Fee Related
- 1990-09-06 DK DK90402449.4T patent/DK0417003T3/da active
- 1990-09-06 KR KR1019900014224A patent/KR0180225B1/ko not_active Expired - Fee Related
- 1990-09-07 JP JP2236004A patent/JP3032258B2/ja not_active Expired - Lifetime
- 1990-09-07 AU AU62259/90A patent/AU623805B2/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0057115A2 (fr) * | 1981-01-09 | 1982-08-04 | Roussel-Uclaf | Nouveaux dérivés stéroides substitués en 11beta, procédé de préparation, leur application comme médicament et les compositions les renfermant |
| FR2625505A2 (fr) * | 1981-01-09 | 1989-07-07 | Roussel Uclaf | Nouveaux derives steroides substitues en 11beta leur procede de preparation et leur application comme medicaments et les compositions pharmaceutiques les renfermant |
| FR2566779A2 (fr) * | 1984-06-29 | 1986-01-03 | Roussel Uclaf | Nouveaux derives steroides substitues en 11b, leur procede de preparation et leur application comme medicaments |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE107859T1 (de) | 1994-07-15 |
| JP3032258B2 (ja) | 2000-04-10 |
| DK0417003T3 (da) | 1994-07-25 |
| JPH0399015A (ja) | 1991-04-24 |
| EP0417003A3 (en) | 1991-12-04 |
| EP0417003A2 (fr) | 1991-03-13 |
| DE69010294D1 (de) | 1994-08-04 |
| DE69010294T2 (de) | 1994-10-27 |
| CA2024728A1 (fr) | 1991-03-08 |
| KR0180225B1 (ko) | 1999-03-20 |
| AU6225990A (en) | 1991-03-14 |
| FR2651435B1 (enExample) | 1994-04-22 |
| KR910005873A (ko) | 1991-04-27 |
| EP0417003B1 (fr) | 1994-06-29 |
| AU623805B2 (en) | 1992-05-21 |
| US5173483A (en) | 1992-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR2651435A1 (fr) | Nouvelle utilisation de composes anti-progestomimetiques. | |
| Webel et al. | The control of ovulation | |
| Martinat-Botte et al. | Control of pig reproductionin a breeding programme | |
| Kumagai et al. | Neonatal exposure to zearalenone causes persistent anovulatory estrus in the rat | |
| US4192870A (en) | Novel zootechnical compositions | |
| FR2505184A1 (fr) | Procede de prevention de la paralysie vitulaire chez la vache laitiere | |
| Howland et al. | Changes in serum levels of gonadotropins and testosterone in the male rat in response to fasting, surgery and ether | |
| Horta et al. | Possibility of reducing the luteolytic dose of cloprostenol in cyclic dairy cows | |
| JPH03500243A (ja) | ２‐デオキシ‐ｄ‐ヘキソースの経口投与による産肉性動物の飼料要求率の改良方法 | |
| WO1997045113A1 (en) | Nsaids for regulating the reproductive cycle of domesticated animals | |
| Thomas et al. | Effects of trenbolone acetate on adrenal function and hepatic enzyme activities in female rats | |
| Lewis et al. | The effect of stilbestrol and anterior pituitary extract upon lactation in goats | |
| CA1177062A (fr) | Procede de preparation de nouveaux derives de l'estra 4,9-diene | |
| US20200375980A1 (en) | Veterinary antiprolactinic composition | |
| JP3241378B2 (ja) | ウシの繁殖力を高めるためのソマトトロピン | |
| Hoffmann | Aspects on the formation and detection of tissue levels of anabolic steroids in domestic animals | |
| Lambert et al. | AI beef management with prostaglandin F2a controlled estrus | |
| RU2794621C1 (ru) | Способ профилактики маститов крупного рогатого скота | |
| US5604214A (en) | Reduction of boar odor in meat | |
| Lederman | An evaluation of estrus suppression in the mare through the use of an altrenogest delivering intravaginal device | |
| FR2475395A1 (fr) | Procede et composition pour augmenter le taux d'ovulation des femelles dans le betail | |
| Heitzman | Anabolic agents in beef production: Their action as growth promoters | |
| Monroe et al. | Metabolism of thyroxine in the goat | |
| EP0688219B1 (en) | Reduction of boar odor in meat | |
| CA1166568A (fr) | Compositions zootechniques renfermant d'une part, le zeranol et d'autre part, un steroide 4,9,11- trienique |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |